Global Biomarker Translation Services Market Size, Share, and COVID-19 Impact Analysis, By Product (Consumables, Services, and Software), By Type (Safety Biomarkers, Efficacy Biomarkers, Predictive Biomarkers, Surrogate Biomarkers, Pharmacodynamic Biomarkers, Prognostics Biomarkers, and Validation Biomarkers), By Disease (Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, and Others), By Application (Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035.

Global Biomarker Translation Services Market Insights Forecasts to 2035

• The Global Biomarker Translation Services Market Size Was Estimated at USD 77.4 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 10.81% from 2025 to 2035
• The Worldwide Biomarker Translation Services Market Size is Expected to Reach USD 239.5 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

The global biomarker translation services market size was worth around USD 77.4 billion in 2024 and is predicted to grow to around USD 239.5 billion by 2035 with a compound annual growth rate (CAGR) of 10.81% from 2025 to 2035. The growing number of patients diagnosed with cancer, along with the growing number of CROs, is driving the biomarker translation services market globally.  

Market Overview

The biomarker translation services market is an industry focusing on the development and validation of biological markers (biomarkers) for use in various applications, such as drug discovery, diagnostics, and personalized medicine. A biomarker is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or biological responses to a therapeutic intervention. Effective translation of preclinical biomarkers into the clinic is paving the way towards effective execution of personalised therapies across complex disease areas for the benefit of patients, healthcare providers, and bio-pharmaceutical industries. Advancements in multiple ‘omics’ (multi-omics) approaches, including genomics, transcriptomics, and proteomics, in combination with bioinformatics and biostatistics, have accelerated the discovery and development of specific biomarkers for complex chronic diseases. The growing application of biomarker technologies in drug development and genome mapping studies, along with the changing inclination towards tailored medications, are bolstering the market growth opportunities for biomarker translation services.

Report Coverage

This research report categorizes the biomarker translation services market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the biomarker translation services market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the biomarker translation services market.

Driving Factors

The increased prevalence of cancer is anticipated to drive the market demand as the biomarker translation research aids in bridging the gap between the results of basic research that identify biomolecules involved in or the consequence of carcinogenesis and their incorporation into medical applications, especially for early detection and screening. It was found that there were about 20 million new cases of cancer in the year 2022, alongside 9.7 million deaths from cancer (including NMSC (nonmelanoma skin cancers)). An increasing preference towards outsourcing biomarker research to CROs by the pharmaceutical and biotech companies, along with an increasing demand for biomarkers in drug development and biomarker-based clinical trials, is contributing to promoting the market.

Restraining Factors

The lack of suitable reimbursement policies and technical challenges are hampering the biomarker translation services market. Further, the increased investment, high capital expenditure, and treatment costs are restricting the market growth.

Market Segmentation

The biomarker translation services market share is classified into product, type, disease, and application.

• The consumables segment dominated the biomarker translation services market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the product, the biomarker translation services market is divided into consumables, services, and software. Among these, the consumables segment dominated the biomarker translation services market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The segment includes assay kits, reagents, and lab supplies that are used in biomarker discovery, validation, and clinical applications.

• The safety biomarkers segment accounted for the largest revenue share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the type, the biomarker translation services market is divided into safety biomarkers, efficacy biomarkers, predictive biomarkers, surrogate biomarkers, pharmacodynamic biomarkers, prognostics biomarkers, and validation biomarkers. Among these, the safety biomarkers segment accounted for the largest revenue share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The biomarkers are used for monitoring and predicting the potential toxicity of drugs in humans, which is critical in the development and approval of new drugs.  An increasing use of safety biomarkers in the evaluation of new candidates, along with the ongoing evaluation of organ/tissue safety biomarkers for use as efficacy biomarkers, is contributing to driving the market

.

• The cancer segment accounted for the dominant market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the disease, the biomarker translation services market is divided into cancer, cardiovascular diseases, neurological diseases, immunological diseases, and others. Among these, the cancer segment accounted for the dominant market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. With the help of biomarker tools, clinicians develop targeted therapies tailored to an individual patient’s tumor characteristics that are most widely used in clinical practice. There is a growing focus on developing biomarkers for cancer diagnostics for improving health and decrease mortality.

• The drug discovery & development segment accounted for the dominant market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the application, the biomarker translation services market is divided into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and others. Among these, the drug discovery & development segment accounted for the dominant market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The growing application of biomarkers in the identification of lead drug candidates and optimization of clinical trials is contributing to driving the market in the drug discovery and development segment.

Regional Segment Analysis of the Biomarker Translation Services Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the biomarker translation services market over the predicted timeframe.

North America is anticipated to hold the largest share of the biomarker translation services market over the predicted timeframe. An upsurging innovation in medical technology is contributing to driving the market growth of biomarker translation services. Further, the substantial R&D investments and regulatory expertise are contributing to propel market growth.  

Asia Pacific is expected to grow at a rapid CAGR in the biomarker translation services market during the forecast period. An increasing health awareness, along with a high disease burden, is expected to propel the biomarker translation services market. Further, the increasing interest of pharmaceutical companies in biomarker-related work in the region is contributing to escalating the market.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the biomarker translation services market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Abbott
• QIAGEN
• PerkinElmer, Inc.
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• Enzo Biochem, Inc.
• Charles River Laboratories International, Inc.
• Eurofins Scientific
• Agilent Technologies, Inc.
• Bruker
• Siemens
• Epigenomics AG
• General Electric
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In February 2022, OncoDNA launched the OncoDeep kit, a disseminated version of its in-house OncoDeep cancer sequencing assay. The kit offers a complete workflow solution incorporating Twist Bioscience's enrichment and library preparation solutions.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the biomarker translation services market based on the below-mentioned segments: 

Global Biomarker Translation Services Market, By Product

• Consumables
• Services
• Software

Global Biomarker Translation Services Market, By Type

• Safety Biomarkers
• Efficacy Biomarkers
• Predictive Biomarkers
• Surrogate Biomarkers
• Pharmacodynamic Biomarkers
• Prognostics Biomarkers
• Validation Biomarkers

Global Biomarker Translation Services Market, By Disease

• Cancer
• Cardiovascular Diseases
• Neurological Diseases
• Immunological Diseases
• Others

Global Biomarker Translation Services Market, By Application

• Diagnostics
• Drug Discovery & Development
• Personalized Medicine
• Disease Risk Assessment
• Others

Global Biomarker Translation Services Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa